国际肿瘤学杂志

国际肿瘤学杂志 ›› 2017, Vol. 44 ›› Issue (8): 704-707.doi: 10.3760/cma.j.issn.1673422X.2017.09.016

• 综述 • 上一篇    下一篇

乳腺癌的延长内分泌治疗

宋方彬, 徐军明, 姚武   

  1. 330006 南昌，江西省人民医院血管乳腺外科（宋方彬、姚武）；上海交通大学附属第一人民医院普外科（徐军明）
  • 出版日期:2017-09-08 发布日期:2017-10-31
  • 通讯作者: 宋方彬，Email: wandianshanmusong@126.com E-mail:wandianshanmusong@126.com

Extended endocrine therapy of breast cancer

Song Fangbin, Xu Junming, Yao Wu   

  1. Department of Vascular and Breast Surgery, People′s Hospital of Jiangxi Province, Nanchang 330006, China
  • Online:2017-09-08 Published:2017-10-31
  • Contact: Song Fangbin E-mail:wandianshanmusong@126.com

PDF

847

摘要： 内分泌治疗是雌激素受体（ER）阳性乳腺癌治疗的重要手段之一，乳腺癌5年辅助内分泌治疗后远期复发却很常见。延长内分泌治疗（EET）是一种很有前景的策略，可进一步降低复发的风险、增加早期患者的治愈机会。EET决策需权衡远期复发风险、月经状态、不良反应及患者意愿，从而个体化实施。未来研究仍需探索哪些患者能从EET中最大获益。

关键词: 乳腺肿瘤, 预后, 他莫昔芬, 内分泌治疗

Abstract: Endocrine therapy is an important treatment of estrogen receptor (ER) positive breast cancer. However, late relapse after completion of 5year adjuvant endocrine therapy is still common. Extended endocrine therapy (EET) is a promising strategy to further reduce the risk of recurrence and increase the cure rate in earlystage patients. The decisionmaking to EET should be individually implemented by weighing the risk of late recurrence, menopausal status, side effects, and patients′ preference. Future studies are still needed to identify the patients who are most likely to benefit from EET.

Key words:  Breast neoplasms, Prognosis, Tamoxifen, Endocrine therapy